The creation and assessment of MPTP-lesioned model of PD in mice

Progress in Biochemistry and Biophysics

Volumn 33, Issue 10, 2006, Pages 1014-1018

  Xu, Yao Gang ^a,b   Pang, Xiao Feng ^a   Ji, Juan Juan ^b  

^a UNIVERSITY OF ELECTRONIC SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Model; Mouse; MPTP; Parkinson's disease

Indexed keywords

ANIMALIA;

EID: 33846328731     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jenner P, Olanow C W. Understanding cell death in Parkinson's disease. Ann Neurol, 1998, 44 (3 Suppl 1): S72-S84
2. Dunnett S B, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature, 1999, 399 (6738 Suppl): 32-39
3. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science, 2000, 287 (5456): 1265-1269
4. Baba M, Nakajo S, Tu P H, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol, 1998, 152 (4): 879-884
5. Mattson M P. Gene-diet interactions in brain aging and neurodegenerative disorders. Ann Intern Med, 2003, 139 (5 Pt 2): 441-444
6. Mouradian M M. Recent advances in the genetics and pathogenesis of Parkinson's disease. Neurology, 2002, 58 (2): 179-185
7. Smith A D, Castro S L, Zigmond M J. Stress-induced Parkinson's disease: a working hypothesis. Physiol Behav, 2002, 77 (4-5): 527-531
8. Warner T T, Schapira A H. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol, 2003, 53 (Suppl 3): S16-S23
9. Feany M B, Bender W W. A Drosophila model of Parkinson's disease. Nature, 2000, 404 (6776): 394-398
10. Haobam R, Sindhu K M, Chandra G, et al. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res, 2005, 163(2): 159-167
11. Jakowec M W, Petzinger G M. 1-Methyl-4-phenyl-1,2,3, 6-tetrahydropyridine lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med, 2004, 54 (5): 497-513
12. Langston J W, Ballard P, Tetrud J W, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219 (4587): 979-980
13. Calne D B, Langston J W, Martin W R, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature, 1985, 317 (6034): 246-248
14. Vingerhoets F J, Snow B J, Tetrud J W, et al. Positron emission tomographic evidence for progression of human MPTP induced dopaminergic lesions. Ann Neurol, 1994, 36 (5): 765-770
15. Javitch J A, D'Amato R J, Strittmatter S M, et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA, 1985, 82 (7): 2173-2177
16. Ramsay R R, Singer T P. Energy-dependent uptake of N-methyl-4- phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine by mitochondria. J Biol Chem, 1986, 261 (17): 7585-7587
17. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39 (6): 889-909
18. +: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic Biol Med, 1993, 15 (2): 169-179
19. Liu Y, Roghani A, Edwards R H. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA, 1992, 89 (19): 9074-9078
20. Jackson-Lewis V, Jakowec M, Burke R E, et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine. Neurodegeneration, 1995, 4 (3): 257-269
21. Freyaldenhoven T E, Ali S F, Hart R W. MPTP and MPP+ induced effects on body temperature exhibit age and strain dependence in mice. Brain Res, 1995, 688 (1-2): 161-170
22. Sedelis M, Hofele K, Auburger G W, et al. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet, 2000, 30 (3): 171-182
23. Mori A, Ohashi S, Nakai M, et al. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res, 2005, 51 (3): 265-274
24. Weissman J, Trevor A, Chiba K, et al. Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. J Med Chem, 1985, 28 (8): 997-1001
25. Yoshihara S, Harada K, Ohta S. Metabolism of 1-methy-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) in perfused rat liver: involvement of hepatic aldehyde oxidase as a detoxification enzyme. Drug Metab Dispos, 2000, 28 (5): 538-543
26. Shimoji M, Zhang L, Mandir A S, et al. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Brain Res Mol Brain Res, 2005, 134 (1): 103-108